Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Monster Beverage Corp (MNST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Monster Beverage Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Monster Beverage Corp trades at $98.39 (market cap $95.25B). The key difference: Monster Beverage Corp is far larger — about 2.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Monster Beverage Corp is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MNST | |
|---|---|---|
Market Cap | $39.89B | $95.25B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $97.64 |
52-Week Low | $278.09 | $58.65 |
Enterprise Value | $38.15B | $93.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Monster Beverage (MNST) trades at $97.39, up 0.87% today, showing strong momentum after recent earnings beats. The stock exhibits a bullish technical trend, with moving averages supporting further upside, while oscillators are neutral. Fundamentally, the company reported robust revenue growth to $8.29 billion in 2025, with a net income margin of 23.11%, and announced a 2-for-1 stock split effective August 2026, reflecting confidence in future performance.
The outlook remains positive given consistent earnings outperformance and international expansion, but high valuation multiples like a P/E of 47.05 pose risks if growth slows. Investor sentiment is buoyed by analyst consensus favoring buys, though competitive pressures and macroeconomic factors warrant caution for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
